Greater Cannabis Company is a clinical-stage biotech developing a cannabinoid-based therapeutic for neuropsychiatric conditions including autism, schizophrenia, Parkinson's disease, and Alzheimer's disease. The company is not a cannabis grower or consumer products company — it is essentially a single-asset drug developer. Its core asset is an exclusive license from Shaare Zedek Scientific Ltd., the technology transfer arm of Jerusalem's Shaare Zedek Medical Center, covering a proprietary cannabinoid therapy candidate. The company completed preclinical studies in early 2024 and received approval from Israel's Ministry of Health to proceed to a Phase II clinical trial, but has not yet started that trial, pending the sourcing of specialized active pharmaceutical ingredients and additional capital. The company has one full-time employee, its CEO, and generates no meaningful revenue. Its business model is oriented toward acting as a licensor rather than a direct drug developer — the stated intention is to rely on sublicensees or strategic partners to fund and execute regulatory approvals, rather than doing so independently. Under the SZS license, the company owes modest annual fees and milestone payments, and would earn royalties of 1–3% on net product sales plus 12% on any sublicensing deals. No sublicensees have been secured. Near-term progress depends entirely on sourcing the required API, raising additional capital, and initiating the Phase II trial, which is expected to take 18–24 months once started.